N/A
N=90
The Role of Proper Insulin Injection Technique in the Treatment of Diabetes Mellitus
Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Lipohypertrophy
Bottom Line
View on ClinicalTrials.gov: NCT04120974 ↗Enrolled (actual)
90
Serious AEs
4.4%
Results posted
Feb 2024
Primary outcome: Primary: Change in Glycemic Control — 8.99; 8.20 % of glycated hemoglobin
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Optimal insulin injection (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Becton, Dickinson and Company
- Primary completion
- Apr 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Glycemic Control |
8.99; 8.20 | — |
| SECONDARY Change in Insulin Total Daily Dose (TDD) |
49.5; 49; 51.2 | — |
| SECONDARY Incidence of Hypoglycemic Events |
56.15; 36.35; 32.28; 74.42; 52.66; 42.62 | — |
| SECONDARY Change in Blood Glucose Levels |
10.28; 11.03; 11.03 | — |
Summary
This is a prospective, post-marketing, single-arm clinical investigation on the effects of optimal insulin injection technique, in conjunction with the use of disposable Becton Dickinson (BD) Micro-Fine Plus 32G pen needles, by Type I and Type II Diabetes Mellitus patients, with or without lipohypertrophy, on clinical outcomes like HbA1c and hypoglycemic events, as well as changes in insulin Total Daily Dose (TDD) and patient's Quality of Life (QoL). During this study, each subject will be trained in the optimal insulin injection technique by personal training as well as by following online video training modules on a specific web-based platform.
Eligibility Criteria
Inclusion Criteria
- Type 1 or type 2 diabetes mellitus;
- At least 1 year of experience with insulin self-administration;
- Use of insulin pen for insulin injections.
- HbA1c > 7.5 % measured at study entry or maximally 30 days prior to screening.
- BMI below 40 kg/m2 at study entry.
- Daily self-control of blood glucose level;
- Access to the internet for watching video lessons.
- Only outpatients are eligible for the study.
- Availability of signed informed consent of the patient for inclusion in the study.
Exclusion Criteria
- Pregnant women or women planning to become pregnant during the time of study, breastfeeding women;
- Subjects using an insulin pump;
- Those using treatment with a Glucagon-Like Peptide (GLP)-1 receptor agonists alone;
- Subjects not fluent in Russian (reading and writing).
- Patients at high risk for ketoacidosis and/or hyperglycemia.
- Psychic, physical or any other reasons hampering patient participation in the study (based on the reasonable opinion of the physician-investigator).
Data sourced from ClinicalTrials.gov (NCT04120974). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.